Lenvima (lenvatinib) — United Healthcare

Initial criteria

• Diagnosis of recurrent adenoid cystic carcinoma

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Lenvima therapy

Approval duration

12 months